Advisory Board

Helen has over twenty-five years’ experience in the Medical device industry including as CEO of Creganna Medical and Product Development and Research roles at Medtronic and Covidien. She has demonstrated the ability to scale, including driving international sales, acquiring and integrating companies, establishing strategic joint ventures and raising of debt and equity financing. During her eight years as CEO of Creganna Medical, the company grew five-fold to become the largest indigenous medical device company.

She now works with Irish companies supporting them to start and scale. She acts as a strategic advisor to Atlantic Bridge Ventures and serves as a director for Enterprise Ireland. She works as an advisor and director for a number of early stage and scaling companies and charities.

Professor Lewis, formerly VP R&D at BTG/Boston Scientific (Biocompatibles UK Ltd.) specializes in the development of advanced biomedical polymer systems, including novel drug-device combination products for use in interventional therapies in the treatment of cardiovascular disease and cancer.

Many of his patented polymer systems have been successfully taken to market; directly or through license agreements. He led the development of the first commercial drug-eluting bead (DEB) technology for the locoregional treatment of malignancies in the liver. The DEB technology is now available globally with hundreds of thousands of procedures having now been performed.

Andy is a recognized expert on biomaterials; having generated over 250 scientific peer-reviewed publications and articles, 12 book chapters and 56 patent families/applications in the fields of polymers, biomaterials and drug delivery with 30+ granted patents in the field of embolization. He also peer-reviews manuscripts for over 25 journals.

Dr Isaacson received his medical degree from the Keck School of Medicine in Los Angeles before completing his diagnostic and interventional radiology training at the University of North Carolina. Dr Isaacson has been a pioneer in the field of embolization.

He worked with the FDA to get approval for and was the co-principal investigator of the first US GAE clinical trial for the treatment of knee osteoarthritis. He went on to be the principal investigator of the pioneering first US sham trial for GAE which definitively demonstrated patient benefit of GAE.

He is a co-director of the highly acclaimed STREAM embolization course; the only conference dedicated exclusively to embolization. He has published a number of peer-reviewed articles on GAE. He currently has a clinical practice in Raleigh, North Carolina and acts as the Chair of Quality and Research for Prostate Centers USA.

Dr. Little is a consultant Interventional Radiologist, and research lead working in Berkshire and London, UK. Dr. Little has established a large embolotherapy research group alongside his busy clinical practice. Dr. Little is currently leading the first European study investigating Genicular Artery Embolization (GAE) in the treatment of knee OA (GENESIS).

He is UK CI for PROstate, an international study investigating long term outcomes of PAE. He is current specialist advisor on the National Institute for Health & Care Excellence (NICE) interventional procedures programme including developing guidelines for GAE in clinical practice. Dr. Little is also a member of the CVIR editorial board.

Dr. Taslakian is a Professor in the Department of Radiology at NYU Grossman
School of Medicine where he serves as the Director of Vascular and Interventional Radiology (VIR) Research Program and the Director of Clinical Research Integration.

Dr. Taslakian has himself been the principal investigator of a very successful GAE clinical
trial. In early 2024, he was the recipient of the JVIR Editor’s Award for Outstanding Clinical
Research. In this trial he used biomarkers to improve the scientific understanding of the
means by which GAE impacts the knee over time. Dr Taslakian is an expert in clinical trial
design with a strong focus on patient satisfaction and patient engagement within the trial. He has regularly lectured on this topic to national and international audiences.

Dr. Stewart is an Assistant Professor of Interventional Radiology at UCLA. She received her MD degree from Stanford University School of Medicine and completed her residency training in Diagnostic Radiology and fellowship in Vascular and Interventional Radiology at Duke University Hospital. Before joining UCLA, she was an assistant professor of Interventional Radiology at the University of North Carolina.

Dr Stewart’s interests include women’s health interventions, such as uterine artery embolization as well as venous embolization. Dr Stewart has been involved with several clinical trials and has conducted research on optimising the Genicular Arterial Embolization procedure for knee osteoarthritis.

Dr Casadaban is a board-certified vascular and interventional radiologist and is Assistant Professor of Interventional Radiology at University of Colorado. Dr Casadaban received her medical degree from the University of Illinois College of Medicine, interned at Massachusetts General Hospital and completed her residency in Brigham and Women’s Hospital/Harvard Medical School and her fellowship with UCLA Medical Center program.

Dr Casadaban is widely recognized for her work in GAE, she was the author of the most referenced meta-analysis of the GAE procedure. This work compared the results of different techniques and patients from operators around the world to help identify and share good practice. Dr Casadaban is a regular presenter at global embolization conferences and has regularly lectured, on the techniques of the procedure, to her peers.

Dr. Padia is a board-certified interventional radiologist and a specialist in vascular and interventional radiology at UCLA Medical Center, with over 20 years of experience in the medical field.
Dr. Padia has a medical degree from Johns Hopkins University School of Medicine. He completed his residency in diagnostic radiology at the Cleveland Clinic and his fellowship in vascular and interventional radiology in Northwestern University. He is dedicated to advancing the field of minimally invasive procedures, particularly in the treatment of chronic knee pain through GAE.

Dr Padia is the principal investigator in two US GAE clinical trials. The first trial “GRAVITY” was successful in proving the benefit of GAE across a broad spectrum of osteoarthritis patients. His combined trials represent the largest clinical dataset for the use of GAE within the United States. Dr Padia is also the principal investigator of a clinical trial using embolization to treat tennis elbow. Dr Padia serves as a consultant to many of the worlds leading medical device companies and he is a member of the SIR (Society of Interventional Radiology) steering group on GAE.

Dr Macaulay is a board-certified orthopedic surgeon and the William and Susan Jaffe Professor of Orthopaedic Surgery at the NYU Grossman School of Medicine.

He received his MD from Columbia University, completed his residency in the University of Pittsburgh School of Medicine and his fellowship at Hospital for Special Surgery in New York, specializing in joint replacement and minimally invasive techniques for hip and knee reconstruction. He is currently the Chief of Adult Reconstructive Surgery Division and Medical Director for International Patient Services, NYU Langone

Dr. Macaulay won the prestigious Lawrence D. Dorr Surgical Techniques and Technologies Award for his significant contributions to the field of hip and knee reconstructive surgery. His research focused on enhancing surgical recovery and improving outcomes for hip and knee replacement surgeries. He is a senior member of the prestigious US Hip Society and US Knee Society, in addition to many other professional organizations